Johnson & Johnson stopped short of implementing its proposal to alter the way two drugs are paid for under the 340B drug discount program, but the drugmaker made it clear it still wants changes. In other recent regulatory news, we have drug approvals, clinical holds, and one product withdrawal.
The post J&J Backs Down From 340B Rebates, But Maintains They’re ‘Legally Permissible’ Per Statute appeared first on MedCity News.
